A phase I/II trial evaluating IV administered MV-NIS either in combination with or without cyclophosphamide (the drug was included to attenuate antiviral immune response) in patients with advanced multiple myeloma (NCT00450814) demonstrated that MV-NIS monotherapy was well-tolerated up to the dose of 1011 TCID50 with no dose limiting toxicities being observed (111, 112). The gene discussed is SLC5A5; the disease is AL amyloidosis.